Regulation of calcium absorption by 1,25,dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.
In 10 patients with Paget's disease of bone and 2 patients with osteoporosis, we studied the effects of hypocalcemia and hypophosphatemia induced by disodium-(3-amino-1-hydroxypropylidene)-1,-bisphosphonate (APD) treatment on the serum concentration of PTH and 1,25-dihydroxy-vitamin D [1,25(OH)2D3] and on calcium absorption and balance. The fall in serum calcium and phosphate was associated with a rise in the serum concentration of PTH and 1,25(OH)2D3, coupled with increases in net calcium absorption and calcium balance. The concentration of 1,25(OH)2D3 was significantly related (P less than 0.001) to the serum calcium (r = 0.66), the serum phosphate (r = 0.78), and the serum PTH (r = 0.71), confirming the interrelated control of these parameters on 1,25(OH)2D3 production. Moreover the rise in 1,25(OH)2D3 caused an appropriate rise in calcium absorption (r = 0.74) and calcium balance (r = 0.86), showing that this vitamin D metabolite contributes as a hormone to calcium homeostasis.
D000368:Aged; D001862:Bone Resorption / Q000187:drug effects; D002117:Calcitriol / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D002118:Calcium / Q000097:blood / Q000378:metabolism*; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced / Q000378:metabolism; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D010024:Osteoporosis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism; D000077268:Pamidronate; D010281:Parathyroid Hormone / Q000097:blood
D004164:Diphosphonates; D010281:Parathyroid Hormone; D002117:Calcitriol; D000077268:Pamidronate; D002118:Calcium